EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
about
Gene aberrations for precision medicine against lung adenocarcinomaDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.EGFR Fusions as Novel Therapeutic Targets in Lung CancerBRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsKinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.Double Trouble: Kinase domain duplication as a new path to drug resistance.The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.Mechanisms of receptor tyrosine kinase activation in cancer.Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants.
P2860
Q26749348-E27FEE00-3A03-4FF2-ABD2-BB5550C7643AQ30762699-9008E61A-9075-4A9D-B2BD-E5E3BAD70AA5Q36264188-9F3CBDD0-597B-460B-A4F3-D5DDEADD5CC0Q36971209-EDF56A72-B146-44CC-8E07-8B8EF25F787AQ37056708-D0724732-2C07-4174-BA50-ACAB40C92F29Q37060709-96D92D39-B81C-495F-9BD9-3C5759238AD1Q38881066-8FB044DB-C4E9-42A2-B111-06B0138D967BQ39346046-09E14C28-1FCC-4875-918D-2EDDDB0363AAQ40344816-474DEEF4-9118-489D-B63E-1404EF52EDF0Q42332097-A339D618-5629-42E4-BD25-5BF1B9308538Q42360041-B9EAC939-736C-4A1A-9B19-1F7B10CA8D9AQ46512789-1E34F10A-0F5E-4A67-AE16-3FBC6B989B10Q47773715-2C7B0AD4-B36D-4A77-9CA8-2821782B8C29Q47804358-1B90B7C1-48FC-4465-B0B8-D06497DBC51BQ49888000-D033C8E9-D45A-42ED-9AA6-5D057EAC0D04Q52767309-5E2ABD6C-5B2B-4F7F-A16D-50E81CCDDB2FQ55289701-C5E423EA-A74F-4F3D-9C17-B111F63C28EF
P2860
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@ast
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@en
type
label
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@ast
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@en
prefLabel
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@ast
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@en
P2093
P2860
P50
P1433
P1476
EGFR Kinase Domain Duplication ...... nically Responsive to Afatinib
@en
P2093
Doron Lipson
Jonathan H Sheehan
Mark Bailey
Monica Red Brewer
Raghu Chandramohan
Sally J York
Siraj M Ali
Vincent A Miller
P2860
P304
P356
10.1158/2159-8290.CD-15-0654
P50
P577
2015-08-18T00:00:00Z